Literature DB >> 27694164

Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art.

Frank K Chen1, Andre Luis de Castro Abreu2, Suzanne L Palmer3.   

Abstract

Prostate cancer screening currently consists of serum prostate-specific antigen and digital rectal examination, followed by transrectal ultrasound-guided biopsy for diagnostic confirmation. Although the current paradigm of prostate cancer screening has led to a decrease in advanced disease and cancer-related mortality, these techniques have limitations in terms of sensitivity and specificity, resulting in missed cancers that are clinically significant and the overdetection of clinically insignificant cancers. New imaging techniques and technologies are required to improve the detection of prostate cancer. This article summarizes the use of novel ultrasound techniques and technologies in the detection, biopsy, and treatment of prostate cancer.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  Doppler ultrasound; MRI/TRUS targeted biopsy; genitourinary; prostate cancer; surveillance biopsy; transrectal ultrasound

Mesh:

Year:  2016        PMID: 27694164     DOI: 10.2967/jnumed.116.177196

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Initial phantom studies for an office-based low-field MR system for prostate biopsy.

Authors:  Selin Chiragzada; Eva Hellman; Duncan Michael; Ram Narayanan; Aleksandar Nacev; Dinesh Kumar
Journal:  Int J Comput Assist Radiol Surg       Date:  2021-04-23       Impact factor: 2.924

2.  Survival and quality of life outcomes of high-intensity focused ultrasound treatment of localized prostate cancer.

Authors:  Peter L Royce; James J Y Ooi; Selva Sothilingam; Henry H Yao
Journal:  Prostate Int       Date:  2020-03-12

3.  Ultrasounds in cancer therapy: A summary of their use and unexplored potential.

Authors:  Jesús Frutos Díaz-Alejo; Itziar González Gómez; Julie Earl
Journal:  Oncol Rev       Date:  2022-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.